These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18393849)

  • 61. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.
    Kon V; Yang H; Fazio S
    Arch Med Res; 2015 Jul; 46(5):379-91. PubMed ID: 26009251
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
    Rocha NA; East C; Zhang J; McCullough PA
    Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
    Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL.
    Ertek S
    Curr Vasc Pharmacol; 2018; 16(5):490-498. PubMed ID: 29149817
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cholesterol metabolism modulators and the future of atherosclerosis therapy].
    Morozova S; Suc-Royer I; Auwerx J
    Med Sci (Paris); 2004; 20(6-7):685-90. PubMed ID: 15329820
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management.
    Johnston TP; Korolenko TA; Pirro M; Sahebkar A
    Pharmacol Res; 2017 Jun; 120():219-225. PubMed ID: 28408313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Advances in the Study of Marine Products with Lipid-Lowering Properties.
    Zhao J; Cao Q; Xing M; Xiao H; Cheng Z; Song S; Ji A
    Mar Drugs; 2020 Jul; 18(8):. PubMed ID: 32726987
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The resurgence of thyromimetics as lipid-modifying agents.
    Tancevski I; Eller P; Patsch JR; Ritsch A
    Curr Opin Investig Drugs; 2009 Sep; 10(9):912-8. PubMed ID: 19705333
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art.
    Vahdat Lasemi F; Mahjoubin Tehran M; Aghaee-Bakhtiari SH; Jalili A; Jaafari MR; Sahebkar A
    Drug Discov Today; 2019 May; 24(5):1116-1131. PubMed ID: 30980904
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report.
    Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members
    J Clin Lipidol; 2014; 8(1):29-60. PubMed ID: 24528685
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The dawn of a new era of targeted lipid-lowering therapies.
    Tokgözoğlu L; Libby P
    Eur Heart J; 2022 Sep; 43(34):3198-3208. PubMed ID: 35051271
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Update on medical management of dyslipidemia and atherosclerosis.
    Ginter E; Simko V
    Bratisl Lek Listy; 2013; 114(5):262-8. PubMed ID: 23611048
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Emerging roles for cholesterol and lipoproteins in lung disease.
    Gowdy KM; Fessler MB
    Pulm Pharmacol Ther; 2013 Aug; 26(4):430-7. PubMed ID: 22706330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.